|
| 37344282 | Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy. | Clin Genitourin Cancer | 2024 |
| 38087732 | Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials. | Eur Urol | 2024 |
| 37714762 | Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. | Eur Urol Oncol | 2024 |
| 37803523 | Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. | BJU Int | 2024 |
| 37951819 | Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010. | Eur Urol Oncol | 2024 |
| 37897615 | Diagnostic accuracy of fully hybrid [<sup>68</sup>Ga]Ga-PSMA-11 PET/MRI and [<sup>68</sup>Ga]Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial. | Eur J Nucl Med Mol Imaging | 2024 |
| 37743194 | European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. | Eur Urol | 2024 |
| 37945451 | The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. | Eur Urol | 2024 |
| 37833180 | Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2022;83:521-33. | Eur Urol | 2024 |
| 37690970 | Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites. | Clin Genitourin Cancer | 2024 |
| 38044179 | Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes. | Eur Urol | 2024 |
| 37775340 | Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites. | Urol Oncol | 2024 |
| 38036666 | Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System. | Nat Rev Urol | 2024 |
| 37423774 | The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. | Eur Urol Oncol | 2024 |
| 37455217 | Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.002. | Eur Urol Focus | 2024 |
| 37414703 | Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data. | Eur Urol | 2024 |
| 35182370 | Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. | J Racial Ethn Health Disparities | 2023 |
| 37865591 | Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS â¿¥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. | Eur Urol Focus | 2023 |
| 37760557 | Predictors of PSMA PET Positivity: Analysis in a Selected Cohort of Biochemical Recurrence Prostate Cancer Patients after Radical Prostatectomy. | Cancers (Basel) | 2023 |
| 37760467 | Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis. | Cancers (Basel) | 2023 |
| 37721691 | In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery. | Ann Surg Oncol | 2023 |
| 37528287 | The Rho-kinase inhibitor Y27632 promotes ureteral relaxation in an in vivo rat model for partial ureteral obstruction. | World J Urol | 2023 |
| 37755519 | Regional differences in clear cell metastatic renal cell carcinoma patients across the USA. | World J Urol | 2023 |
| 37755520 | The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS⿿⿥⿿3 lesions. | World J Urol | 2023 |
| 37627838 | [<sup>68</sup>Ga]Ga-PSMA and [<sup>68</sup>Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration. | Bioengineering (Basel) | 2023 |
| 37558516 | Conditional survival of stage III non-seminoma testis cancer patients. | Urol Oncol | 2023 |
| 37748951 | Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005. | Eur Urol Focus | 2023 |
| 37483849 | The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. | Cent European J Urol | 2023 |
| 38060038 | Vertical Light Non-Aqueous Phase Liquid (LNAPL) distribution by Rn prospecting in monitoring wells. | Environ Monit Assess | 2023 |
| 37845121 | Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. | Eur Urol Oncol | 2023 |
| 37698646 | The potential role of osteoporosis in unspecific [<sup>18</sup>F]PSMA-1007 bone uptake. | Eur J Nucl Med Mol Imaging | 2023 |
| 37509408 | Immunonutrition in Radical Cystectomy: State of the Art and Perspectives. | Cancers (Basel) | 2023 |
| 37787591 | Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries. | Can Urol Assoc J | 2023 |
| 37739916 | The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade. | Eur Urol Focus | 2023 |
| 37506474 | Regional differences in penile cancer patient characteristics and treatment rates across the United States. | Cancer Epidemiol | 2023 |
| 37835425 | Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis. | Cancers (Basel) | 2023 |
| 37777767 | Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer. | BMC Urol | 2023 |
| 37640983 | Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls. | Int Urol Nephrol | 2023 |
| 37568309 | Endoscopic Conservative Treatment of Upper Urinary Tract Urothelial Carcinoma with a Thulium Laser: A Systematic Review. | J Clin Med | 2023 |
| 38036328 | Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration. | Eur Urol Oncol | 2023 |
| 37815682 | Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era. | Ann Surg Oncol | 2023 |
| 37671725 | Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter. | J Urol | 2023 |
| 37599159 | Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47. | Eur Urol | 2023 |
| 37530704 | The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. | Curr Opin Urol | 2023 |
| 37530661 | Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. | Minerva Urol Nephrol | 2023 |
| 35850976 | The Surgical Learning Curve for Biochemical Recurrence After Robot-assisted Radical Prostatectomy. | Eur Urol Oncol | 2023 |
| 37326656 | Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer. | World J Urol | 2023 |
| 37221827 | Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. | Minerva Urol Nephrol | 2023 |
| 37024421 | Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients. | Eur Urol Focus | 2023 |
| 37217391 | Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. | Eur Urol | 2023 |